Every material Form 8-K Janux Therapeutics, Inc. has filed with the SEC since June 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Janux Therapeutics reported third-quarter 2026 results for the period ended September 30, 2026. Collaboration revenue was $9.3 million, down from $10.0 million a year earlier, while the net loss narrowed to $21.6 million from $24.3 million, helped by lower research and development and general and administrative expenses. The company reported $945.7 million in cash, cash equivalents and short-term investments and said initial clinical data for JANX011 will be presented on November 9, 2026.
Q3 2026 collaboration revenue was $9.3 million, versus $10.0 million in Q3 2025; nine-month revenue was $23.3 million, versus $10.0 million.
Q3 2026 net loss was $21.6 million, or $0.34 per share, versus $24.3 million, or $0.39 per share, a year earlier.
Research and development expenses were $30.6 million, down from $34.6 million; general and administrative expenses were $10.0 million, down from $10.6 million.
Cash, cash equivalents and short-term investments were $945.7 million at September 30, 2026, versus $966.6 million at December 31, 2025.
Janux Therapeutics reported results for the three months ended June 30, 2026, with a net loss of $22.0 million, down from $33.9 million a year earlier. The company also recorded $10.3 million of collaboration revenue, compared with none in the same quarter of 2025, and ended the quarter with $970.9 million in cash, cash equivalents and short-term investments.
Net loss per share was $0.35 for the quarter, compared with $0.55 in the second quarter of 2025.
Collaboration revenue was $10.3 million in the quarter, versus no collaboration revenue in the prior-year quarter.
Research and development expenses fell to $31.0 million from $34.7 million, while general and administrative expenses rose to $11.0 million from $10.5 million.
Cash and short-term investments were $970.9 million at June 30, 2026, up from $966.6 million at December 31, 2025.
On June 23, 2026, Chief Medical Officer William Go left Janux Therapeutics. The company determined the departure was a termination without Cause under its Change in Control and Severance Benefit Plan. Janux has started a search for a successor, and existing clinical leaders will cover his responsibilities in the interim, with the company saying its development strategy, regulatory plans and previously disclosed clinical timelines are unaffected.
Departure of William Go, M.D., Ph.D., as Chief Medical Officer effective June 23, 2026
Company classified the exit as a termination without Cause under its Change in Control and Severance Benefit Plan
Search for a successor has begun; members of the existing clinical leadership team are assuming his duties in the interim
Company states the departure was not the result of any disagreement on operations, policies or practices
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Janux Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →